CNS Pharmaceuticals, Inc.
CNSP · XNASCIK 1729427fmd_1GYVB78E9PSHXWNKZKVDK4JWZ4Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Jun 30, 2026, 34 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 0 | 2 | 5 | 10 | 9 | 14 | 9 | 10 |
| Total operating expenses | 1 | 4 | 9 | 14 | 15 | 19 | 15 | 16 |
| Compensation and benefits | – | – | – | – | 0 | – | – | – |
| Operating income | (1) | (4) | (9) | (14) | (15) | (19) | (15) | (16) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | (7) | (0) | (0) | (0) | (0) | 0 | 0 | 0 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (7) | (4) | (9) | (14) | (15) | (19) | (15) | (16) |